Earnings per share for the last twelve months: Bicara Therapeutics Inc (BCAX)

The head and neck tumor therapy market is currently taking shape, experiencing an acute shortage of innovation. Comparing the TTM revenue per share metric on GURU.Markets, we see that the latest value is recorded as -3.47. Bicara Therapeutics Inc. (BCAX) is creating a unique system for targeted cancer impact, implementing new efficiency standards. Business scaling relies on patents and outsourced production, which will ensure high margins for the company.
Metric breakdowns and analytics for Bicara Bio (BCAX)

To stress-test positions, it is critical for an investor to evaluate the net income distributed per share over the last four quarters, which determines the real business yield without accounting for capital dilution. For Bicara Therapeutics Inc. (BCAX), whose success depends on the clinical development phases of antibodies, the rolling earnings per share metric on GURU.Markets serves as an indicator of the transition from burning raised capital to achieving operational efficiency.